ArticleCytoJournal2024
Utility of fine-needle aspiration cytology combined with flow cytometry in extramedullary hematolymphoid lesions - A cross-sectional study.
Article in CytoJournal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Destaining hematoxylin and eosin stains and restaining for immunohistochemistry has diagnostic value for cytology samples.CytoJournal · 2026Article
- Transfer RNA-derived fragment tRF-28-P4R8YP9LOND5 as a novel serum biomarker for gastric cancer: diagnostic efficacy and clinicopathological correlations.Translational cancer research · 2025Article
- Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Flow cytometry (FC) can be an adjunct to fine-needle aspiration cytology (FNAC) in the diagnosis and subclassification of hematolymphoid lesions. This study evaluates the utility of FC in diagnosing extramedullary hematolymphoid lesions in fine-needle aspirate samples. Material and Methods: This cross-sectional study enrolled patients who presented to the FNAC clinic and suspected to have hematolymphoid lesions (nodal and extra nodal lesions) from August 2020 to June 2022. Sixty-seven cases of hematolymphoid malignancies and 67 cases without hematolymphoid malignancies were included. The combined FNAC/FC diagnosis was compared with the gold standard: Biopsy, cell block, or peripheral blood/bone marrow aspirate FC. Results: Of 67 lymphoma cases, 63 were of the primary type and 4 were diagnosed with suspected recurrence/residual disease. Moreover, 57 cases were nodal, and 10 were extranodal. Four of the patients had discordant findings between FNAC and FC. The gold standard was available only in 56 cases, of which 5 had discordant findings between combined FNAC/FC and the gold standard. We subclassified 34 cases based on combined FNAC/FC. The five cases included anaplastic large cell lymphoma (1/5), classic Hodgkin lymphoma (3/5), and one case of atypical lymphoid hyperplasia. Non-contributory FC was attributed to the presence of large cells/necrosis/nodular lymphocyte predominant Hodgkin lymphoma/metastasis/Castleman disease/technical problem. Conclusion: Combining FC with FNAC enhances diagnostic accuracy and helps subclassify lymphoma. Future works should explore whether it can replace excision biopsy, especially in recurrent cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.